Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005816 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Stage III or Stage IV Kidney Cancer
A Phase 1 study of Kidney Cancer, sponsored by Duke University.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT00005816 is a Phase 1 study of Kidney Cancer that has completed, run by Duke University. The registered enrollment target is 15 participants, below the 880-participant average among 60 other Kidney Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00005816, a Phase 1 study of Kidney Cancer, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have stage III or stage IV kidney cancer.
Conditions Studied
Interventions
- PROCEDURE conventional surgery
- BIOLOGICAL therapeutic autologous dendritic cells
Study Locations (1)
North Carolina
- Duke Comprehensive Cancer Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2000-02 |
| Est. Completion | 2002-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005816
The ClinicalTrials.gov registry entry for NCT00005816 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 880-participant average among 60 other Kidney Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Kidney Cancer appearing as the primary indexed condition, and to 2 interventions - of which conventional surgery is the first listed.
NCT00005816 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT00005816 about?
NCT00005816 is a clinical study titled "Vaccine Therapy in Treating Patients With Stage III or Stage IV Kidney Cancer". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have stage III or stage IV kidney cancer.
What is the current status of trial NCT00005816?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2000-02. Estimated completion is 2002-08.
What conditions does trial NCT00005816 study?
This clinical trial studies the following conditions: Kidney Cancer.
What interventions are being tested in trial NCT00005816?
The interventions under investigation include: conventional surgery (PROCEDURE), therapeutic autologous dendritic cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT00005816?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005816 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
-
A Study of VET3-TGI in Patients With Solid Tumors
RECRUITING · Phase 1
-
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer
ACTIVE NOT RECRUITING · Phase 1
-
NeoVax Plus Ipilimumab in Renal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 1
-
A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.